Medical Marijuana, Inc. Subsidiary Kannaway® Opens New Office and Warehouse in Warsaw, Poland
Medical Marijuana, Inc. (OTC: MJNA) announced the opening of a new 7,771 square foot office and warehouse in Warsaw, Poland, enhancing its capability to distribute CBD products across Europe. The facility is located near key transport links and will service over 30 countries, following strict safety protocols. CEO Blake Schroeder expressed optimism for growth and legislative advancements in the cannabis sector. The European CBD market is projected to grow significantly, with a compound annual growth rate (CAGR) of over 33.5% from 2021 to 2027, following a size of $1.9 billion in 2020.
- New office and warehouse in Warsaw offers improved distribution capabilities.
- Facility allows shipping to over 30 countries in Europe.
- European CBD market forecasted to grow at over 33.5% CAGR.
- None.
SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® has opened a new office and warehouse in Warsaw, Poland.
The new 7,771 square foot warehouse is strategically positioned near the Warsaw airport and city center, making it easily accessible for employees and visitors. The facility allows Kannaway® to use the Polish Post, DPD, and UPS to ship its high-quality cannabidiol (CBD) products to more than 30 countries in Europe. The warehouse operations follow Hazard Analysis Critical Control Points (HACCP) and Good Hygiene Practice (GHP).
“Our company introduced CBD to the European marketplace. This new facility will allow us to further our growth while also improving our service levels,” said Kannaway® CEO Blake Schroeder. “This year is predicted to bring significant progress for positive cannabis legislative changes and we look forward to helping many countries that are establishing their cannabis and CBD markets by offering them safe, accurately-labeled products of the highest quality.”
According to Graphical Research, the European CBD market size surpassed
To learn more about Kannaway®, please visit the Company online at https://www.kannaway.com/.
About Kannaway®
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact:
Kathryn Brown
Account Director
CMW Media
P. 858-264-6600
kathryn@cmwmedia.com
www.cmwmedia.com
Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com
FAQ
What new facility did Medical Marijuana, Inc. open?
How will the new facility impact CBD distribution?
What is the projected growth of the European CBD market?
What is the stock symbol for Medical Marijuana, Inc.?
